This HTML5 document contains 91 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00621/identifier/national-drug-code-directory/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n25http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n15http://linked.opendata.cz/resource/drugbank/dosage/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00621/identifier/chemspider/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00621/identifier/chebi/
n7http://bio2rdf.org/drugbank:
n26http://linked.opendata.cz/resource/drugbank/drug/DB00621/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n30http://linked.opendata.cz/resource/drugbank/drug/DB00621/identifier/pharmgkb/
n10http://linked.opendata.cz/resource/drugbank/patent/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00621/identifier/kegg-compound/
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00621/identifier/pubchem-compound/
n24http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n9http://www.drugs.com/cdi/
n13http://www.rxlist.com/cgi/generic2/
n11http://linked.opendata.cz/resource/drugbank/property/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00621/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00621/identifier/kegg-drug/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00621/identifier/drugbank/
n17http://linked.opendata.cz/resource/atc/
n16http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00621
rdf:type
n3:Drug
n3:description
A synthetic hormone with anabolic and androgenic properties. [PubChem]
n3:dosage
n15:271B5883-363D-11E5-9242-09173F13E4C5 n15:271B5884-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Demling RH, DeSanti L: Oxandrolone induced lean mass gain during recovery from severe burns is maintained after discontinuation of the anabolic steroid. Burns. 2003 Dec;29(8):793-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14636753
n3:group
investigational approved
n3:halfLife
0.55 hours (1st phage), 9 hours (2nd phase)
n3:indication
Use to promote weight gain after weight loss following extensive surgery.
n3:manufacturer
n4:271B587B-363D-11E5-9242-09173F13E4C5 n4:271B5879-363D-11E5-9242-09173F13E4C5 n4:271B587A-363D-11E5-9242-09173F13E4C5 n4:271B587D-363D-11E5-9242-09173F13E4C5 n4:271B587C-363D-11E5-9242-09173F13E4C5
owl:sameAs
n6:DB00621 n7:DB00621
dcterms:title
Oxandrolone
adms:identifier
n19:7820 n20:5667 n21:46509027 n22:5878 n23:D00462 n26:Oxandrolone n27:0245-0271-11 n28:DB00621 n29:C07346 n30:PA164749395
n3:mechanismOfAction
Oxandrolones interact with androgen receptors in target tissues.
n3:packager
n4:271B5877-363D-11E5-9242-09173F13E4C5 n4:271B5878-363D-11E5-9242-09173F13E4C5 n4:271B5871-363D-11E5-9242-09173F13E4C5 n4:271B5872-363D-11E5-9242-09173F13E4C5 n4:271B586F-363D-11E5-9242-09173F13E4C5 n4:271B5870-363D-11E5-9242-09173F13E4C5 n4:271B5875-363D-11E5-9242-09173F13E4C5 n4:271B5876-363D-11E5-9242-09173F13E4C5 n4:271B5873-363D-11E5-9242-09173F13E4C5 n4:271B5874-363D-11E5-9242-09173F13E4C5 n4:271B586D-363D-11E5-9242-09173F13E4C5 n4:271B586E-363D-11E5-9242-09173F13E4C5 n4:271B586B-363D-11E5-9242-09173F13E4C5 n4:271B586C-363D-11E5-9242-09173F13E4C5
n3:patent
n10:5872147 n10:6670351
n3:synonym
Protivar Oxandrolona Oxandrolon Ossandrolone Oxandrolonum Oxandrolone
n3:toxicity
The oral LD50 of oxandrolone in mice and dogs is greater than 5,000 mg/kg.
n3:synthesisReference
John Cabaj, "Process for the synthesis of oxandrolone." U.S. Patent US20030032817, issued February 13, 2003.
n24:hasConcept
n25:M0015635
foaf:page
n9:oxandrolone.html n13:oxandrolone.htm
n3:IUPAC-Name
n11:271B5889-363D-11E5-9242-09173F13E4C5
n3:InChI
n11:271B588F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n11:271B588E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n11:271B588B-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n11:271B588C-363D-11E5-9242-09173F13E4C5
n3:SMILES
n11:271B588D-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n11:271B5887-363D-11E5-9242-09173F13E4C5
n3:logP
n11:271B589F-363D-11E5-9242-09173F13E4C5 n11:271B5885-363D-11E5-9242-09173F13E4C5 n11:271B5888-363D-11E5-9242-09173F13E4C5
n3:logS
n11:271B5886-363D-11E5-9242-09173F13E4C5
n16:hasATCCode
n17:A14AA08
n3:H-Bond-Acceptor-Count
n11:271B5895-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n11:271B5896-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n11:271B5890-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n11:271B5891-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n11:271B5893-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n11:271B5892-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n11:271B5894-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
53-39-4
n3:category
n3:containedIn
n12:271B5882-363D-11E5-9242-09173F13E4C5 n12:271B5880-363D-11E5-9242-09173F13E4C5 n12:271B5881-363D-11E5-9242-09173F13E4C5 n12:271B587E-363D-11E5-9242-09173F13E4C5 n12:271B587F-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n11:271B589A-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n11:271B589C-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n11:271B589D-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n11:271B589E-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n11:271B5899-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n11:271B5898-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n11:271B589B-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n11:271B588A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n11:271B5897-363D-11E5-9242-09173F13E4C5